Therapeutic antibodies:
Saved in:
| Format: | Book |
|---|---|
| Language: | English |
| Published: |
London [u.a.]
Springer
1995
|
| Subjects: | |
| Online Access: | Inhaltsverzeichnis |
| Item Description: | Literaturangaben |
| Physical Description: | XII, 231 S. Ill., graph. Darst. |
| ISBN: | 3540197222 0387197222 |
Staff View
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV009962209 | ||
| 003 | DE-604 | ||
| 005 | 20160322 | ||
| 007 | t | ||
| 008 | 941223s1995 ad|| |||| 00||| eng d | ||
| 016 | 7 | |a 943148413 |2 DE-101 | |
| 020 | |a 3540197222 |9 3-540-19722-2 | ||
| 020 | |a 0387197222 |9 0-387-19722-2 | ||
| 035 | |a (OCoLC)611588076 | ||
| 035 | |a (DE-599)BVBBV009962209 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 |a DE-19 |a DE-29T | ||
| 050 | 0 | |a RM282.I44 | |
| 082 | 0 | |a 615/.37 |2 20 | |
| 084 | |a XD 3115 |0 (DE-625)152552:12921 |2 rvk | ||
| 245 | 1 | 0 | |a Therapeutic antibodies |c J. Landon ... (eds.) |
| 264 | 1 | |a London [u.a.] |b Springer |c 1995 | |
| 300 | |a XII, 231 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 500 | |a Literaturangaben | ||
| 650 | 7 | |a Antistoffen |2 gtt | |
| 650 | 7 | |a Immunoglobulinen |2 gtt | |
| 650 | 7 | |a Immunotherapie |2 gtt | |
| 650 | 7 | |a Katalyse |2 gtt | |
| 650 | 7 | |a Tumoren |2 gtt | |
| 650 | 7 | |a Vergiftiging |2 gtt | |
| 650 | 4 | |a Antibodies |x therapeutic use | |
| 650 | 4 | |a Antitoxins | |
| 650 | 4 | |a Immunoglobulins |x Therapeutic use | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Immunotherapy |x methods | |
| 650 | 0 | 7 | |a Immuntherapie |0 (DE-588)4026640-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Therapie |0 (DE-588)4059798-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Antikörper |0 (DE-588)4002290-0 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Antikörper |0 (DE-588)4002290-0 |D s |
| 689 | 0 | 1 | |a Therapie |0 (DE-588)4059798-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Antikörper |0 (DE-588)4002290-0 |D s |
| 689 | 1 | 1 | |a Immuntherapie |0 (DE-588)4026640-0 |D s |
| 689 | 1 | |5 DE-604 | |
| 700 | 1 | |a Landon, John |d 1931- |e Sonstige |0 (DE-588)1079185852 |4 oth | |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006602264&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
Record in the Search Index
| _version_ | 1805082780842852352 |
|---|---|
| adam_text |
CONTENTS
PREFACE
.
IX
CONTRIBUTORS
.
XI
1
AN
INTRODUCTION
TO
THE
CLINICAL
APPLICATIONS
OF
ANTIBODIES
J.
LANDON,
T.
CHARD
AND
R.E.
COXON
.
1
HISTORY
.
1
TYPES
AND
SOURCES
OF
ANTIBODIES
.
3
DIAGNOSTIC
APPLICATIONS
.
7
THERAPEUTIC
APPLICATIONS
.
10
POTENTIAL
SIDE-EFFECTS
.
21
ANTICIPATED
DEVELOPMENTS
AND
CONCLUSIONS
.
28
REFERENCES
.
31
2
BIOLOGY
OF
THE
IMMUNE
RESPONSE
T.
POULTON
AND
F.
HAY
.
33
INTRODUCTION
.
33
INNATE
IMMUNE
SYSTEM
.
33
ADAPTIVE
IMMUNITY
.
35
A
TYPICAL
IMMUNE
RESPONSE
.
38
IMMUNOGLOBULIN
STRUCTURE
AND
FUNCTION
.
39
REFERENCES
.
45
3
ANTIBODY
PRODUCTION
IN
THE
HEN
'
J.
LANDON,
J.A.
WOOLLEY
AND
C.
MCLEAN
.
47
SUMMARY
.
47
BACKGROUND
.
48
COMPARISON
OF
AVIAN
AND
MAMMALIAN
ANTIBODY
PRODUCTION
.
55
USES
OF
AVIAN
ANTIBODIES
.
57
ALTERNATIVES
TO
AVIAN
ANTIBODIES
FOR
THERAPY
.
65
REFERENCES
.
66
4
CATALYTIC
ANTIBODIES
G.
GALLACHER
.
69
INTRODUCTION
.
69
VI
THERAPEUTIC
ANTIBODIES
CATALYSIS
VIA
TRANSITION-STATE
COMPLEMENTARITY
.
69
ANTIBODY-CATALYSED
HYDROLYSIS
OF
LABILE
ESTERS
.
70
HYDROLYSIS
OF
MORE-STABLE
COMPOUNDS
.
75
CATALYSIS
VIA
OTHER
STRATEGIES
.
76
CATALYSIS
OF
OTHER
TYPES
OF
REACTION
.
79
POLYCLONAL
CATALYTIC
ANTIBODIES
.
81
DEVELOPING
THERAPEUTIC
CATALYTIC
ANTIBODIES
.
83
CONCLUSION
.
86
REFERENCES
.
86
5
IMMUNOTHERAPY
FOR
DRUG
TOXICITY
A.J.
HEATH
.
89
INTRODUCTION
.
89
DIGOXIN
.
91
COLCHICINE
.
102
TRICYCLIC
ANTIDEPRESSANTS
.
104
REFERENCES
.
106
6
THERAPEUTIC
ANTIBODIES
TO
SNAKE
VENOMS
R.D.G.
THEAKSTON
AND
D.C.
SMITH
.
109
HISTORY
.
109
STANDARD
METHODS
OF
ANTIVENOM
PRODUCTION
.
109
DIFFERENT
TYPES
OF
AVAILABLE
ANTIVENOMS
.
110
ANTIVENOM
REACTIONS
.
ILL
METHODS
OF
ANTIVENOM
POTENCY
ASSESSMENT
.
112
RECENT
DEVELOPMENTS
IN
ANTIVENOM
PRODUCTION
.
115
CONCLUSIONS
.
128
REFERENCES
.
128
7
THERAPEUTIC
ANTIBODIES
TO
TUMOURS
J.A.
LEDERMANN
.
135
INTRODUCTION
.
135
CELL
SURFACE
TARGETS
FOR
ANTIBODY
THERAPY
.
136
BIODISTRIBUTION
OF
ANTIBODIES
.
136
THERAPEUTIC
STRATEGIES
.
138
LIMITATIONS
OF
ANTIBODY
THERAPY
.
145
CONCLUSIONS
.
148
REFERENCES
.
149
8
THERAPEUTIC
ANTIBODIES
TO
MICROORGANISMS
P.L.
YAP
.
153
INTRODUCTION
.
153
ANTIBODY
PREPARATIONS
AVAILABLE
FOR
PROPHYLAXIS
AND
TREATMENT
OF
INFECTIONS
.
154
APPLICATIONS
OF
IM
IGG
PREPARATIONS
FOR
PROPHYLAXIS
OF
VIRAL
INFECTION
.
156
APPLICATIONS
OF
IVIG
THERAPY
.
160
CONTENTS
VII
USE
OF
IVIG
PREPARATIONS
FOR
PREVENTION
AND
TREATMENT
OF
SPECIFIC
INFECTION
.
169
CONCLUSION
.
172
REFERENCES
.
173
9
IMMUNOLOGICAL
THERAPY
OF
ENDOTOXAEMIA:
ANTI-ENDOTOXIN
ANTIBODIES
A.P.
WHEELER
AND
G.R.
BERNARD
.
177
INTRODUCTION
.
177
THE
ROLE
OF
ENDOTOXIN
IN
SEPSIS
.
177
ENDOTOXIN:
RELATIONSHIP
OF
STRUCTURE
TO
FUNCTION
.
.
.
178
APPROACHES
TO
ENDOTOXIN
ANTAGONISM
.
179
MECHANISM
OF
ANTI-ENDOTOXIN
ANTIBODY
ACTION
.
180
THE
USE
OF
ANTI-CORE
ANTIBODIES
.
180
IMPACT
OF
ANTI-CORE
ANTIBODY
CLASS
AND
TITRE
ON
EFFICACY
181
PROSPECTIVE
STUDIES
OF
HUMAN
POLYCLONAL
CORE
ANTISERUM
.
182
STUDIES
WITH
ANTI-CORE/LIPID
A
MONOCLONAL
ANTIBODIES
185
IMPACT
OF
ANTI-ENDOTOXINS
ON
CYTOKINE
GENERATION
IN
HUMAN
SEPSIS
.
189
ADVANTAGES
AND
LIMITATIONS
OF
ANTI-ENDOTOXIN
ANTIBODIES
.
190
SUMMARY
.
191
REFERENCES
.
*191
10
CYTOKINE
ANTIBODIES
AND
ANTAGONISTS
IN
THE
TREATMENT
OF
SEPSIS
A.P.
WHEELER
AND
K.L.
BRIGHAM
.
199
INTRODUCTION
.
199
TOXIN
INITIATION
OF
SEPSIS
.
199
PROPERTIES
OF
TNF,
IL-1,
IL-6
AND
THEIR
RECEPTORS
.
.
.
200
CYTOKINE
INTERACTIONS
IN
INFLAMMATION
.
202
EVIDENCE
THAT
CYTOKINES
ARE
INVOLVED
IN
SEPSIS
.
203
THERAPEUTIC
STRATEGIES
.
208
SUMMARY
.
212
REFERENCES
.
212
INDEX
.
225 |
| any_adam_object | 1 |
| author_GND | (DE-588)1079185852 |
| building | Verbundindex |
| bvnumber | BV009962209 |
| callnumber-first | R - Medicine |
| callnumber-label | RM282 |
| callnumber-raw | RM282.I44 |
| callnumber-search | RM282.I44 |
| callnumber-sort | RM 3282 I44 |
| callnumber-subject | RM - Therapeutics and Pharmacology |
| classification_rvk | XD 3115 |
| ctrlnum | (OCoLC)611588076 (DE-599)BVBBV009962209 |
| dewey-full | 615/.37 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615/.37 |
| dewey-search | 615/.37 |
| dewey-sort | 3615 237 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000 c 4500</leader><controlfield tag="001">BV009962209</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20160322</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">941223s1995 ad|| |||| 00||| eng d</controlfield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">943148413</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3540197222</subfield><subfield code="9">3-540-19722-2</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0387197222</subfield><subfield code="9">0-387-19722-2</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)611588076</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV009962209</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-29T</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM282.I44</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.37</subfield><subfield code="2">20</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XD 3115</subfield><subfield code="0">(DE-625)152552:12921</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Therapeutic antibodies</subfield><subfield code="c">J. Landon ... (eds.)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">London [u.a.]</subfield><subfield code="b">Springer</subfield><subfield code="c">1995</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XII, 231 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Literaturangaben</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antistoffen</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immunoglobulinen</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immunotherapie</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Katalyse</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Tumoren</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Vergiftiging</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antibodies</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antitoxins</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunoglobulins</subfield><subfield code="x">Therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunotherapy</subfield><subfield code="x">methods</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Immuntherapie</subfield><subfield code="0">(DE-588)4026640-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Antikörper</subfield><subfield code="0">(DE-588)4002290-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Antikörper</subfield><subfield code="0">(DE-588)4002290-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Antikörper</subfield><subfield code="0">(DE-588)4002290-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Immuntherapie</subfield><subfield code="0">(DE-588)4026640-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Landon, John</subfield><subfield code="d">1931-</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)1079185852</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006602264&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield></record></collection> |
| id | DE-604.BV009962209 |
| illustrated | Illustrated |
| indexdate | 2024-07-20T07:38:06Z |
| institution | BVB |
| isbn | 3540197222 0387197222 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-006602264 |
| oclc_num | 611588076 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR DE-19 DE-BY-UBM DE-29T |
| owner_facet | DE-355 DE-BY-UBR DE-19 DE-BY-UBM DE-29T |
| physical | XII, 231 S. Ill., graph. Darst. |
| publishDate | 1995 |
| publishDateSearch | 1995 |
| publishDateSort | 1995 |
| publisher | Springer |
| record_format | marc |
| spelling | Therapeutic antibodies J. Landon ... (eds.) London [u.a.] Springer 1995 XII, 231 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Literaturangaben Antistoffen gtt Immunoglobulinen gtt Immunotherapie gtt Katalyse gtt Tumoren gtt Vergiftiging gtt Antibodies therapeutic use Antitoxins Immunoglobulins Therapeutic use Immunotherapy Immunotherapy methods Immuntherapie (DE-588)4026640-0 gnd rswk-swf Therapie (DE-588)4059798-2 gnd rswk-swf Antikörper (DE-588)4002290-0 gnd rswk-swf Antikörper (DE-588)4002290-0 s Therapie (DE-588)4059798-2 s DE-604 Immuntherapie (DE-588)4026640-0 s Landon, John 1931- Sonstige (DE-588)1079185852 oth DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006602264&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Therapeutic antibodies Antistoffen gtt Immunoglobulinen gtt Immunotherapie gtt Katalyse gtt Tumoren gtt Vergiftiging gtt Antibodies therapeutic use Antitoxins Immunoglobulins Therapeutic use Immunotherapy Immunotherapy methods Immuntherapie (DE-588)4026640-0 gnd Therapie (DE-588)4059798-2 gnd Antikörper (DE-588)4002290-0 gnd |
| subject_GND | (DE-588)4026640-0 (DE-588)4059798-2 (DE-588)4002290-0 |
| title | Therapeutic antibodies |
| title_auth | Therapeutic antibodies |
| title_exact_search | Therapeutic antibodies |
| title_full | Therapeutic antibodies J. Landon ... (eds.) |
| title_fullStr | Therapeutic antibodies J. Landon ... (eds.) |
| title_full_unstemmed | Therapeutic antibodies J. Landon ... (eds.) |
| title_short | Therapeutic antibodies |
| title_sort | therapeutic antibodies |
| topic | Antistoffen gtt Immunoglobulinen gtt Immunotherapie gtt Katalyse gtt Tumoren gtt Vergiftiging gtt Antibodies therapeutic use Antitoxins Immunoglobulins Therapeutic use Immunotherapy Immunotherapy methods Immuntherapie (DE-588)4026640-0 gnd Therapie (DE-588)4059798-2 gnd Antikörper (DE-588)4002290-0 gnd |
| topic_facet | Antistoffen Immunoglobulinen Immunotherapie Katalyse Tumoren Vergiftiging Antibodies therapeutic use Antitoxins Immunoglobulins Therapeutic use Immunotherapy Immunotherapy methods Immuntherapie Therapie Antikörper |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006602264&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT landonjohn therapeuticantibodies |